He graduated with a BA in Physiological Sciences from the University of Oxford in 1979. He then studied Medicine which he completed in 1982 from the University of Oxford and obtained a DPhil from the same university in 1994. Prof. Craddock underwent post-graduate training in hematology at the Hammersmith Hospital, London, the Institute of Molecular Medicine at the University of Oxford and the Fred Hutchinson Cancer Research Centre at the University of Washington, Seattle.
His main research interests include the design and delivery of new drug and transplant therapies in myeloid malignancies, development of novel reduced intensity conditioning regimens, immunotherapeutic strategies and improving outcomes after alternative donor transplants particularly recipients of cord blood transplants.
Prof. Charles Craddock is Director of Centre for Clinical Haematology, the Chair of UK Stem Cell Strategic Forum and was a past President of the British Society of Blood and Marrow Transplantation. In addition, he is the leader of the UK haemato-oncology Trials Acceleration Programme devoted to the design of novel drug and transplant therapies in these diseases. Prof. Charles Craddock is also a member of the NCRN AML Working Party and Industry Liaison Group.